ImageneBio
IMA
27 hedge funds and large institutions have $539M invested in ImageneBio in 2021 Q1 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
64.12% more ownership
Funds ownership: 0% → 64.12% (+64%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$108M |
| 2 |
OrbiMed
New York
|
+$83.7M |
| 3 |
Omega Fund Management
Boston,
Massachusetts
|
+$64.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$58.6M |
| 5 |
BVF Inc
San Francisco,
California
|
+$45.7M |
Top Sellers
IMA Hedge Fund Activity: Q1 2021 in Review
27 of the 5,715 institutional investors tracked by Wall St. Rank reported a position in ImageneBio (IMA) for Q1 2021, worth a combined $539M.
Buyers outnumbered sellers: 27 funds opened new IMA positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $108M.
- 27 institutional investors held ImageneBio (IMA) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $539M of ImageneBio stock for Q1 2021.
- 27 funds opened new ImageneBio positions in Q1 2021 and 0 closed out, a net change of +27 holders.
- The largest ImageneBio buyer in Q1 2021 was Fidelity Investments, an estimated $108M added.
Based on aggregated 13F filings for Q1 2021.